Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With,CEBPAMutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

作者: Guido Marcucci , Kati Maharry , Michael D. Radmacher , Krzysztof Mrózek , Tamara Vukosavljevic

DOI: 10.1200/JCO.2008.17.5554

关键词:

摘要: PurposeTo evaluate the prognostic significance of CEBPA mutations in the context of established molecular markers in cytogenetically normal (CN) acute myeloid leukemia (AML) and gain biologic insights into leukemogenesis of the CN-AML molecular high-risk subset (FLT3 internal tandem duplication [ITD] positive and/or NPM1 wild type) that has a significantly higher incidence of CEBPA mutations than the molecular low-risk subset (FLT3-ITD negative and NPM1 mutated).Patients and MethodsOne hundred seventy-five adults age less than 60 years with untreated primary CN-AML were screened before treatment for CEBPA, FLT3, MLL, WT1, and NPM1 mutations and BAALC and ERG expression levels. Gene and microRNA (miRNA) expression profiles were obtained for the CN-AML molecular high-risk patients.ResultsCEBPA mutations predicted better event-free (P = .007), disease-free (P = .014), and overall survival (P < .001) independently of other molecular and clinical prognosticators. Among patients with CEBPA mutations, 91% were in the CN-AML molecular high-risk group. Within this group, CEBPA mutations predicted better event-free (P < .001), disease-free (P = .004), and overall survival (P = .009) independently of other molecular and clinical characteristics and were associated with unique gene and miRNA expression profiles. The major features of these profiles were upregulation of genes (eg, GATA1, ZFPM1, EPOR, and GFI1B) and miRNAs (ie, the miR-181 family) involved in erythroid differentiation and downregulation of homeobox genes.ConclusionPretreatment testing for CEBPA mutations identifies CN-AML patients with different outcomes, particularly in the molecular high-risk group, thus improving molecular risk-based classification of this large cytogenetic subset of AML. The gene and miRNA expression profiling provided insights into leukemogenesis of the CN-AML molecular high-risk group, indicating that CEBPA mutations are associated with partial erythroid differentiation.

参考文章(52)
Claus Nerlov, C/EBPalpha mutations in acute myeloid leukaemias. Nature Reviews Cancer. ,vol. 4, pp. 394- 400 ,(2004) , 10.1038/NRC1363
Tapani Ruutu, Sakari Knuutila, Krzysztof Mrózek, Steven A. Schichman, Geoffrey P. Herzig, Clara D. Bloomfield, Matthew P. Strout, AnneMarie W. Block, Diane C. Arthur, Tapio Nousiainen, Philip Schulman, Kristiina Heinonen, Carlo M. Croce, Charles A. Schiffer, Michael A. Caligiuri, Maria R. Baer, Jens Pedersen-Bjergaard, Partial Tandem Duplication of ALL1 as a Recurrent Molecular Defect in Acute Myeloid Leukemia with Trisomy 11 Cancer Research. ,vol. 56, pp. 1418- 1425 ,(1996)
Christian Thiede, Sina Koch, Eva Creutzig, Christine Steudel, Thomas Illmer, Markus Schaich, Gerhard Ehninger, , Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. ,vol. 107, pp. 4011- 4020 ,(2006) , 10.1182/BLOOD-2005-08-3167
Guido Marcucci, Michael D. Radmacher, Kati Maharry, Krzysztof Mrózek, Amy S. Ruppert, Peter Paschka, Tamara Vukosavljevic, Susan P. Whitman, Claudia D. Baldus, Christian Langer, Chang-Gong Liu, Andrew J. Carroll, Bayard L. Powell, Ramiro Garzon, Carlo M. Croce, Jonathan E. Kolitz, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield, MicroRNA expression in cytogenetically normal acute myeloid leukemia The New England Journal of Medicine. ,vol. 358, pp. 1919- 1928 ,(2008) , 10.1056/NEJMOA074256
B Argiropoulos, R K Humphries, Hox genes in hematopoiesis and leukemogenesis Oncogene. ,vol. 26, pp. 6766- 6776 ,(2007) , 10.1038/SJ.ONC.1210760
Hiromi Iwasaki, Shin-ichi Mizuno, Richard A Wells, Alan B Cantor, Sumiko Watanabe, Koichi Akashi, GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages Immunity. ,vol. 19, pp. 451- 462 ,(2003) , 10.1016/S1074-7613(03)00242-5
Konstanze Döhner, Richard F. Schlenk, Marianne Habdank, Claudia Scholl, Frank G. Rücker, Andrea Corbacioglu, Lars Bullinger, Stefan Fröhling, Hartmut Döhner, , Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. ,vol. 106, pp. 3740- 3746 ,(2005) , 10.1182/BLOOD-2005-05-2164
P. Zhang, G. Behre, J. Pan, A. Iwama, N. Wara-aswapati, H. S. Radomska, P. E. Auron, D. G. Tenen, Z. Sun, Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 96, pp. 8705- 8710 ,(1999) , 10.1073/PNAS.96.15.8705
Susan P. Whitman, Amy S. Ruppert, Michael D. Radmacher, Krzysztof Mrózek, Peter Paschka, Christian Langer, Claudia D. Baldus, Jing Wen, Frederick Racke, Bayard L. Powell, Jonathan E. Kolitz, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield, FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications Blood. ,vol. 111, pp. 1552- 1559 ,(2008) , 10.1182/BLOOD-2007-08-107946